Stage
No active trials
Next date
None yet
Trials
0 active
2 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Pulmonary Arterial Hypertension (PAH), Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH), CML
- Main trialPhase 2
- “This is a randomized, double-blind, multi-center, placebo-controlled dose-ranging clinical trial of two IkT-001Pro doses in patients with PAH designed to assess safety, tolerability and efficacy. It will enroll approximately 150 participants at up to 50 sites globally. The study consists of two parts, a 26 week placebo controlled treatment period (Part A) followed by a 36 month extension period (Part B).”In the company’s words, NCT06643143 on ClinicalTrials.gov
Other drugs for Pulmonary Arterial Hypertension (PAH)
- RalinepagUnited Therapeutics · Phase 3
- SeralutinibGB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc. · Phase 3
- Treprostinil PalmitilInsmed Incorporated · Phase 3
- MacitentanActelion · Phase 3
- Macitentan/Tadalafil FDCActelion · Phase 3
- SelexipagActelion · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Withdrawn | 30 Jun 2027 | A Phase 2 Study of IkT-001Pro in Pulmonary Arterial Hypertension (PAH) | |
| Phase 1Completed | 30 Jun 2024 | A Dose Calibration Study Comparing IkT-001Pro to Imatinib Mesylate 400mg |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026